![](https://endpts.com/wp-content/uploads/2016/10/stencil.twitter-post-123.png)
SEC subpoenaes BioMarin in drisapersen probe; Job hunting? The FDA has hundreds of open positions
BioMarin $BMRN has more headaches to contend with on its Duchenne muscular dystrophy drug drisapersen. The company says in its newly posted quarterly report with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.